



US 20210261961A1

(19) **United States**(12) **Patent Application Publication**
COSTA et al.(10) **Pub. No.: US 2021/0261961 A1**(43) **Pub. Date: Aug. 26, 2021**(54) **ANTISENSE OLIGONUCLEOTIDES
TARGETING TIA1**(71) Applicant: **Hoffmann-La Roche Inc.**, Little Falls,
NJ (US)(72) Inventors: **Veronica COSTA**, Basel (CH); **Heidi
Rye HUDLEBUSCH**, Brønshøj (DK);
Ravi JAGASIA, Loerrach (DE);
Dheeraj MALHOTRA, Basel (CH);
Lykke PEDERSEN, Copenhagen NV
(DK)(21) Appl. No.: **17/245,443**(22) Filed: **Apr. 30, 2021****Related U.S. Application Data**(63) Continuation of application No. PCT/EP2019/
079583, filed on Oct. 30, 2019.(30) **Foreign Application Priority Data**

Nov. 1, 2018 (EP) 18203935.4

Publication Classification(51) **Int. Cl.**
C12N 15/113 (2006.01)(52) **U.S. Cl.**
CPC **C12N 15/113** (2013.01); **C12N 2310/11**
(2013.01); **C12N 2310/3231** (2013.01); **C12N**
2310/341 (2013.01); **C12N 2310/351**
(2013.01); **C12N 2310/346** (2013.01); **C12N**
2310/3341 (2013.01); **C12N 2310/315**
(2013.01)(57) **ABSTRACT**

The present invention relates to antisense oligonucleotides (oligomers) complementary to nucleic acids encoding mammalian T cell-restricted intracellular antigen-1 (TIA1), in particular antisense oligonucleotides targeting TIA1 pre-mRNA sequences, which are capable of inhibiting the expression of TIA1. Inhibition of TIA1 expression is beneficial for a range of medical disorders including neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) or Frontotemporal Dementia.

Specification includes a Sequence Listing.